ArticleScientific reports2025
The unique relationship between body mass index and metabolic syndrome in AIDS patients.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prolonged Exposure to Antiretroviral Therapy and Risk of Developing Hypertension Among HIV-Infected Clinic Attendees: A Pilot Study in Rural Eastern Cape Province, South Africa.International journal of environmental research and public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic syndrome (MS) poses substantial health risks for people living with HIV/AIDS (PLWHA). While body mass index (BMI) is a well-established predictor of MS in the general population, its association with MS in PLWHA remains poorly characterized, particularly in China. This study investigates the relationship between BMI and MS in Chinese AIDS patients, with emphasis on population-specific metabolic risk patterns and threshold deviations from general population benchmarks. We enrolled 482 hospitalized AIDS patients stratified by BMI categories: underweight (< 18.5 kg/m², n = 92), normal weight (18.5-23.9 kg/m², n = 311), and overweight/obese (≥ 24 kg/m², n = 79). MS diagnosis followed Chinese Diabetes Society (CDS) criteria. Comparative analyses of blood pressure, fasting glucose, and lipid profiles were conducted across groups. Statistical approaches included Spearman correlation for BMI-MS associations, multivariate logistic regression (adjusted for age, sex, and metabolic parameters), and ROC curve analysis to determine BMI thresholds predictive of MS. The overall MS prevalence was 8.92% (43/482), with striking disparities between groups: overweight/obese patients demonstrated 3.5-fold higher MS prevalence than normal-weight counterparts (24.1% vs. 6.8%, P < 0.001). Metabolic derangements were disproportionately elevated in the overweight/obese group, including hypertension (31.6% vs. 12.2%) and hypertriglyceridemia (44.3% vs. 21.5%, both P < 0.05). BMI showed strong positive correlations with MS diagnosis (r = 0.42, P < 0.001) and MS component burden (r = 0.38, P < 0.001). Multivariate analysis identified BMI as an independent MS predictor (adjusted OR = 1.15 per unit increase, 95% CI:1.06-1.25, P < 0.05). ROC analysis revealed a clinically relevant BMI cut-off of 20 kg/m² for MS prediction (AUC = 0.79), substantially lower than general population thresholds. This study identifies an accentuated BMI-MS relationship in Chinese PLWHA, with metabolic complications emerging at atypically low BMI values. The proposed BMI threshold of 20 kg/m² for MS risk stratification-25% below standard obesity criteria. Urgent adoption of HIV-specific metabolic screening is needed, prioritizing early BMI-guided interventions to reduce cardiovascular risks, even in non-obese individuals.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.